Animal rights advocates are decrying a recent report noting that animal parts from three endangered species are ingredients in three Chinese pharmaceuticals.
Reuters originally reported that the three publicly traded Chinese pharmaceutical companies are the Beijing Tong Ren Tang Group, Tianjin Pharmaceutical Group, and Jilin Aodong Pharmaceutical Group.
The Daily Caller reported the three pharmaceutical groups listed body parts of endangered animals as ingredients in their traditional Chinese (TCM) medical products.
Endangered leopards and pangolins, for example, were noted as ingredients in 88 TNC products, according to an investigative report by the Environmental Investigation Agency (EIA) U.K. Sunday.
The EIA has called on partners and investors to withdraw support from these firms. Financial investors include the larger banks USB and HSBC, BlackRock, Citigroup and Deutsche Bank.
In all, 62 financial institutions have investments in at least one of the three Chinese pharmaceutical companies utilizing body parts from endangered species in their products.
Avinash Basker, a policy specialist representing the NGO, wrote in a press release: “It’s particularly disappointing to see so many major banks and financial institutions effectively endorsing this damaging exploitation. They need to divest from TCM manufacturers using threatened species at the soonest opportunity.”
Animal advocates at the recent Convention on International Trade in Endangered Species (CITES) of Wild Fauna and Flora released a list of 52 recommendations to address the issue.
Referencing these recommendations, Basker said: “We strongly urge the Government of China to fulfill CITES recommendations and prohibit the use of the body parts of leopards, pangolins, tigers, and rhinos from all sources for all commercial purposes in its domestic markets.”
Scroll down to leave a comment and share your thoughts.